Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-PD1/PDL1 Antibody”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Large-scale testing (Phase 3)WithdrawnNCT04203511
What this trial is testing

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Who this might be right for
Non-small Cell Lung Cancer
Incyte Corporation
Testing effectiveness (Phase 2)Looking for participantsNCT06941857
What this trial is testing

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Early research (Phase 1)Active Not RecruitingNCT05878691
What this trial is testing

GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Who this might be right for
Advanced Solid TumorLymphoma
Glenmark Specialty S.A. 320
Testing effectiveness (Phase 2)Looking for participantsNCT06580574
What this trial is testing

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Who this might be right for
Gastric CancerColon CancerMSI-H+1 more
Peking University 34
Large-scale testing (Phase 3)Looking for participantsNCT06926868
What this trial is testing

Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Who this might be right for
Breast Neoplasms
Bristol-Myers Squibb 600
Large-scale testing (Phase 3)Active Not RecruitingNCT06500026
What this trial is testing

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Who this might be right for
Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 722
Testing effectiveness (Phase 2)Study completedNCT03727880
What this trial is testing

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma
Lei Zheng 28
Testing effectiveness (Phase 2)Looking for participantsNCT06482801
What this trial is testing

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Who this might be right for
Liver CancerAntibody
Second Affiliated Hospital of Guangzhou Medical University 90
Not applicableUnknownNCT04943679
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 15
Testing effectiveness (Phase 2)Study completedNCT05578872
What this trial is testing

ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Who this might be right for
Melanoma (Skin)Cutaneous MelanomaAdult Disease+2 more
Anaveon AG 29
Testing effectiveness (Phase 2)Ended earlyNCT03379259
What this trial is testing

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
BeiGene 39
Not applicableLooking for participantsNCT06537908
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 50
Not applicableNot Yet RecruitingNCT05660213
What this trial is testing

Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

Who this might be right for
Unresectable Hepatocellular Carcinoma
Fudan University 750
Large-scale testing (Phase 3)Active Not RecruitingNCT05785767
What this trial is testing

Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals 149
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07774611
What this trial is testing

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd. 180
Testing effectiveness (Phase 2)Ended earlyNCT04438382
What this trial is testing

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSteroid-Refractory Pneumonitis
ECOG-ACRIN Cancer Research Group 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT05605496
What this trial is testing

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Centre Leon Berard 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT05604560
What this trial is testing

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Who this might be right for
Pancreatic Cancer
Lei Zheng 25
Not applicableUnknownNCT04860076
What this trial is testing

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Who this might be right for
MelanomaLung Cancer
Asylia Diagnostics BV 400
Next Page